Cleared Traditional

K150852 - SIC 8000 (FDA 510(k) Clearance)

Class II Gastroenterology & Urology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K150852 · Cosmo Technologies, Ltd. · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2015
Decision
156d
Days
Class 2
Risk

K150852 is an FDA 510(k) clearance for the SIC 8000. Classified as Submucosal Injection Agent (product code PLL), Class II - Special Controls.

Submitted by Cosmo Technologies, Ltd. (Dublin 1, IE). The FDA issued a Cleared decision on September 3, 2015 after a review of 156 days - an extended review cycle.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.1500 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Gastroenterology & Urology review framework, consistent with the majority of Class II 510(k) submissions.

View all Cosmo Technologies, Ltd. devices

Submission Details

510(k) Number K150852 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 31, 2015
Decision Date September 03, 2015
Days to Decision 156 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
26d slower than avg
Panel avg: 130d · This submission: 156d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code PLL Submucosal Injection Agent
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 876.1500
Definition Intended For Use In Gastrointestinal Endoscopic Procedures For Submucosal Lift Of Polyps, Adenomas, Early-stage Cancers Or Other Gastrointestinal Mucosal Lesions, Prior To Excision With A Snare Or Endoscopic Device.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Gastroenterology & Urology devices follow this clearance model.

Regulatory Peers - PLL Submucosal Injection Agent

All 8
Devices cleared under the same product code (PLL) and FDA review panel - the closest regulatory comparables to K150852.
Blue Eye
K241591 · The Standard Co., Ltd. · Jul 2024
Blue Eye (TS-905)
K220434 · The Standard Co., Ltd. · Aug 2022
LiftUp (Ref. Nr.: 200.56.01), LiftUp Kit (Ref. Nr.: 200.56.02)
K221385 · Ovesco Endoscopy AG · Aug 2022
Blue Beacon Submucosal Injectable Solution
K200071 · Micro-Tech (Nanjing) Co., Ltd. · Nov 2020
EverLift Submucosal Lifting Agent
K202376 · Gi Supply, Inc. · Sep 2020
EverLift Submucosal Lifting Agent
K191923 · Gi Supply · Jun 2020